The fibrotic disease drug developer, which had raised $50m from investors including Shire, will be bought for $390m upfront and up to $1bn in milestone payments.

The drug discovery startup, co-founded by research technology producer Atomwise, has pulled in $14.5m through a round led by DCVC Bio.

Each Friday, the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Radiology analytics software developer Enlitic secured follow-on funding from its strategic partners Marubeni and Capitol Health with the launch of its first product due next year.

Alexandria Venture Investments, Brace Pharma Capital and Takeda Ventures have contributed to the round, which included a $15m commitment from Eli Lilly made earlier this year.

Based on research from Brigham Young University and University of Utah, Sera has added $36m to its funding vault to drive commercialisation of its blood testing system PreTRM.

OUP returned for PMV's series C round which the company will use to cement its portfolio of small molecule treatments targeting cancerous p53 mutations.

Building on UCSD intellectual property, EpicentRx is working on immunotherapy drugs intended to target the body's non-specific and adaptive specific immune function synchronously.

LabCorp, the lead investor in Sera’s series C round in 2017, has returned for a $36m series D round that will drive commercialisation of the blood testing system PreTRM.